🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

CHARM Hepatocellular Carcinoma MEA Study

Recruitingn/aAges any - anyAllAstraZeneca
NCT07650773 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third reason for cancer-related death worldwide. Cirrhosis is a common risk factor of HCC, as it is found in approximately 70-90% of patients with HCC. Hepatitis C (HCV) and alcohol consumption represent the main causes of cirrhosis and HCC in Western countries; however, hepatitis B virus (HBV) is the leading cause of HCC and cirrhosis in East Asia and Africa. Moreover, HBV and HCV are considered the most common causes of HCC in about 80%-90% of patients. In addition, steatotic liver disease (SLD) is considered one of the main causes of HCC and cirrhosis. Unfortunately, the burden of HCC is great in Middle Eastern and North African (MENA) countries because of the high prevalence of HCV and HBV and the increasing incidence of SLD and metabolic-associated steatohepatitis (MASH). Several studies illustrated

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with a radiological or histopathological confirmed diagnosis with HCC in any stage of the tumor between 1st January 2015 and 31st December 2023 (defined as index date). * Patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver is granted) willing and able to provide written informed consent according to the local regulations * Age 18 years or older, and a lawful adult in the country at the index date * Patients with medical records, including etiology, laboratories, radiological, and treatment details will be collected from the participating sites. * Patients with medical records covering at least a 6-month follow-up period, defined as the time from the index date (the date of the first diagnosis) to the earliest of the following: the patient's death, the last medical record entry, or the data extraction date. Additionally, patients who died within this 6-month period will also be included. Exclusion Criteria: * Patients with other cancer diagnosis on or before index date. * Patients with records missing information on etiology, laboratory results, radiological findings, or treatment details (≥30% of key variables). * Previously opted out of sharing medical records * Patients participating in clinical trials * Pregnant patient
💊

What it tests

  • Not listed
📍

Where

17 sites
Research Site
Al Mansurah, Egypt
Research Site
Dakahlia, Egypt
Research Site
Damietta, Egypt
Research Site
Menouf, Egypt
Research Site
Kuwait City, Kuwait
Research Site
Rabat, Morocco
Research Site
Doha, Qatar
Research Site
Dammam, Saudi Arabia

…and 9 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy